Drug Repurposing: Escitalopram attenuates acute lung injury by inhibiting the SIK2/ HDAC4/ NF-κB signaling cascade

Title
Drug Repurposing: Escitalopram attenuates acute lung injury by inhibiting the SIK2/ HDAC4/ NF-κB signaling cascade
Authors
Keywords
Salt-inducible kinase 2 (SIK2), Escitalopram, Histone deacetylase 4 (HDAC4), Acute lung injury, Drug repurposing
Journal
Publisher
Elsevier BV
Online
2022-02-08
DOI
10.1016/j.bbrc.2022.02.015

Ask authors/readers for more resources

Reprint

Contact the author

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started